1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardinam JW. WHO classification of tumors of haematopoietic and lymphoid tissues Lyon: IARC press; 2008;.
2. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities
3. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection
4. Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M. High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol 2005;23:877-880.
5. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient